M2 Presswire - Understand how Schering-Ploughs ethical sales are set to grow at a 2004-2010 CAGR of 7.4%, driven by Remicade, Zetia/Vytorin and the Intron franchise.
M2 PRESSWIRE-15 February 2006-Research and Markets: Understand how Schering-Ploughs ethical sales are set to grow at a 2004-2010 CAGR of 7.4, driven by Remicade, Zetia/Vytorin and the Intron franchise(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:15022006 Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c32975) has announced the addition of Schering-Plough: PharmaVitae Profile 2005 to their offering This analysis examines the current position and future outlook for Schering-Plough in the ethical pharmaceutical sector.
Most Popular
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
Public Speaking: 7 Secrets Of Great Public Speakers
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
The profile encompasses global strategy, …
Read the rest of this article with a Free Trial at HighBeam Research.
